Pasithea Therapeutics Corp.
KTTA
$0.58
$0.000.76%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.70M | 8.71M | 7.11M | 6.79M | 6.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.89M | 16.69M | 13.86M | 13.76M | 13.89M |
| Operating Income | -17.89M | -16.69M | -13.86M | -13.76M | -13.89M |
| Income Before Tax | -19.73M | -20.43M | -13.49M | -13.46M | -13.61M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.73 | -20.43 | -13.49 | -13.46 | -13.61 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.73M | -20.43M | -13.49M | -13.46M | -13.61M |
| EBIT | -17.89M | -16.69M | -13.86M | -13.76M | -13.89M |
| EBITDA | -17.23M | -16.03M | -13.19M | -13.11M | -13.24M |
| EPS Basic | -1.98 | -3.47 | -5.21 | -7.68 | -10.72 |
| Normalized Basic EPS | -1.03 | -1.96 | -3.26 | -4.80 | -6.70 |
| EPS Diluted | -1.98 | -3.47 | -5.21 | -7.68 | -10.72 |
| Normalized Diluted EPS | -1.03 | -1.96 | -3.26 | -4.80 | -6.70 |
| Average Basic Shares Outstanding | 50.19M | 28.07M | 16.55M | 10.15M | 5.55M |
| Average Diluted Shares Outstanding | 50.19M | 28.07M | 16.55M | 10.15M | 5.55M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |